TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17239277

Group type: EXPERIMENTAL
Intervention: Microarray analysis for gene expression profiling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of differential expression, chromosomal alteration, and pathways signature analysis
Number of subjects: 0
Study: 14725610

Group type: EXPERIMENTAL
Intervention: Caffeine-containing coffee
Number of subjects: 12

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 12
Study: 11774270

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer using serum prostate-specific antigen (PSA) and digital rectal examination (DRE) as an ancillary test.
Number of subjects: 102691

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer in the ERSPC trial.
Number of subjects: 102691

Group type: EXPERIMENTAL
Intervention: Screening adherence in the intervention arm.
Number of subjects: 102691

Group type: EXPERIMENTAL
Intervention: Population-based centers with randomization prior to consent.
Number of subjects: 102691

Group type: COMPARATOR
Intervention: Comparison of mean age-specific PSA levels between PLCO and ERSPC trials.
Number of subjects: 102691
Study: 9419169

Group type: EXPERIMENTAL
Intervention: Valaciclovir, 8 g/day
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Acyclovir, 3.2 or 0.8 g/day
Number of subjects: 1227
Study: 8575495

Group type: EXPERIMENTAL
Intervention: 60 MU
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 100 MU
Number of subjects: 127
Study: 2539346

Group type: EXPERIMENTAL
Intervention: Ro 03-8799 (0.75 g/m2) and SR 2508 (2 g/m2) administered three times per week for 15 doses
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ro 03-8799 (0.75 g/m2) and SR 2508 (2 g/m2) administered three times per week for 12 doses
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ro 03-8799 and SR 2508 combination
Number of subjects: 26
Study: 311458

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 31385620

Group type: EXPERIMENTAL
Intervention: Blue Line Ultra Suctionaid (BLUSA) talking tracheostomy tube (Smiths Medical)
Number of subjects: 22
Study: 31223399

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of ketoprofen 100mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lidocaine and prilocaine topical cream
Number of subjects: 300

Group type: COMPARATOR
Intervention: Physiological saline solution (placebo)
Number of subjects: 300
Study: 27558280

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M) 40 mg
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M) (all doses)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Olmesartan medoxomil (OLM) 20 mg
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 26499123

Group type: EXPERIMENTAL
Intervention: Grade-6 HIV-prevention intervention
Number of subjects: 3924

Group type: EXPERIMENTAL
Intervention: Grade-10 HIV-risk reduction intervention
Number of subjects: 3924

Group type: EXPERIMENTAL
Intervention: Combined child and parent-child HIV-risk reduction interventions
Number of subjects: 3924

Group type: EXPERIMENTAL
Intervention: Both grade-6 and grade-10 interventions
Number of subjects: 3924
Study: 23250194

Group type: EXPERIMENTAL
Intervention: Concurrent physical activity (PA)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: 6-month physical activity (PA)
Number of subjects: 356
Study: 23082419

Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring and identification of the external branch of the superior laryngeal nerve (EBSLN) during thyroid surgery.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group with no identification of EBSLN during thyroid surgery.
Number of subjects: 42
Study: 19293130

Group type: EXPERIMENTAL
Intervention: Immediate switch to 4.6 mg/24 h rivastigmine transdermal patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed switch to 4.6 mg/24 h rivastigmine transdermal patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Donepezil 5-10 mg/day
Number of subjects: 0
Study: 17501956

Group type: EXPERIMENTAL
Intervention: TCHM (Chinese herbal medicine concoction), 3 capsules twice daily for 12 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo, 3 capsules twice daily for 12 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: TCHM (Chinese herbal medicine concoction)
Number of subjects: 85
Study: 15494274

Group type: EXPERIMENTAL
Intervention: Early hydrocortisone treatment (n = 9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Early hydrocortisone treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11847472

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.15 IU/kg/day)
Number of subjects: 27
Study: 9218038

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization (TUEVAP) with VaporTrode‐Grooved Bar, CIRCON ACMI, power settings 120 to 190 W.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP), power settings 120 to 190 W.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization (TUEVAP) in large prostates.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization (TUEVAP) in small prostates.
Number of subjects: 12
Study: 8263071

Group type: EXPERIMENTAL
Intervention: 99mTc-bicisate
Number of subjects: 105

Group type: COMPARATOR
Intervention: 133Xe
Number of subjects: 105
Study: 2889554

Group type: EXPERIMENTAL
Intervention: Bopindolol (2 mg, administered orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bopindolol (2 to 4 mg, administered orally)
Number of subjects: 10
Study: 28857785

Group type: EXPERIMENTAL
Intervention: LMA‐S
Number of subjects: 106

Group type: COMPARATOR
Intervention: i‐gel
Number of subjects: 106
Study: 27160490

Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium sulphate (375 μg/rat) prior to intrathecal morphine (10 μg/rat)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intrathecal mixture of 1 mg of morphine with 3 mL hyperbaric 0.5% bupivacaine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intrathecal mixture of morphine with bupivacaine and 50 mg of magnesium sulphate
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intrathecal mixture of morphine bupivacaine plus IV 20 mg/kg of magnesium sulphate as a loading dose over 15 min, followed by infusion at a rate of 10 mg/kg/h
Number of subjects: 3
Study: 24895810

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) plus standard medical treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 70
Study: 22266041

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (E1594 and E4599)
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Bevacizumab treatment (E4599)
Number of subjects: 1590
Study: 20543666

Group type: EXPERIMENTAL
Intervention: Automated oscillometric BP measuring device (eBPM)
Number of subjects: 3776

Group type: COMPARATOR
Intervention: Conventional AuscBPM
Number of subjects: 3776

Group type: EXPERIMENTAL
Intervention: eBPM
Number of subjects: 3776
Study: 18408919

Group type: EXPERIMENTAL
Intervention: 60 mg tandospirone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15900355

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Indoramin 25 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Atenolol 50 mg (non-chewing controls)
Number of subjects: 63
Study: 12611560

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of antioxidants
Number of subjects: 0
Study: 10875051

Group type: EXPERIMENTAL
Intervention: Drug treatment (mainly antidepressants)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cognitive‐behaviour therapy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Self‐help therapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Life events (conflict events)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Life events (loss and addition events)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Personality characteristics (flamboyant and dependent personality disorders)
Number of subjects: 210
Study: 8897030

Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 50% VO2max (two 30-min bouts with 45 min rest)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sitting at 23 degrees C for 3 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sitting at 40 degrees C, 30% relative humidity for 3 hours
Number of subjects: 11
Study: 1400010

Group type: EXPERIMENTAL
Intervention: 4 ng.kg‐1.min‐1 epinephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 16 ng.kg‐1.min‐1 epinephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 64 ng.kg‐1.min‐1 epinephrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2860180

Group type: EXPERIMENTAL
Intervention: 1% povidone-iodine (PVP-I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 56
Study: 29992608

Group type: EXPERIMENTAL
Intervention: Teen PEP (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed implementation of Teen PEP (comparison group)
Number of subjects: 0
Study: 26869460

Group type: EXPERIMENTAL
Intervention: One daily physical exercise unit at school for 4 years
Number of subjects: 366

Group type: COMPARATOR
Intervention: Conventional school sports twice a week
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: One daily physical exercise unit at school
Number of subjects: 366
Study: 26573456

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 34
Study: 23116325

Group type: EXPERIMENTAL
Intervention: HP-hCG
Number of subjects: 147

Group type: COMPARATOR
Intervention: r-hCG
Number of subjects: 147
Study: 21851602

Group type: EXPERIMENTAL
Intervention: Green tea extract containing 150 mg EGCG two times daily
Number of subjects: 2534

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2534
Study: 18676350

Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoetin alfa
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intravenous darbepoetin alfa
Number of subjects: 114
Study: 16367882

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg once daily plus glipizide 10 mg twice daily
Number of subjects: 227

Group type: COMPARATOR
Intervention: Sulphonylurea (SU) dose escalation plus placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) plus glipizide
Number of subjects: 227

Group type: COMPARATOR
Intervention: Sulphonylurea (SU) dose escalation
Number of subjects: 227
Study: 12635001

Group type: EXPERIMENTAL
Intervention: Concentrated ambient particulates (CAP) at an average concentration of 174 micro g/m(3) for 2 hours with alternating rest-exercise periods.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Filtered air (FA) as control.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Concentrated ambient particulates (CAP) exposure.
Number of subjects: 24
Study: 10982510

Group type: EXPERIMENTAL
Intervention: Bougie group (56F bougie)
Number of subjects: 171

Group type: COMPARATOR
Intervention: No bougie group
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Bougie group
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study: 8630131

Group type: EXPERIMENTAL
Intervention: Emergency Departments (EDs)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Private Practitioners
Number of subjects: 123
Study: 1360991

Group type: COMPARATOR
Intervention: Diphenhydramine (50 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Phenindamine (25 mg)
Number of subjects: 27
Study: 6581756

Group type: EXPERIMENTAL
Intervention: Bright artificial light therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 29
Study: 31577721

Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercise (TSE) with a 1-repetition maximum resistance level of 70%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercise (TSE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study: 29503316

Group type: EXPERIMENTAL
Intervention: Physician
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Provider type (physician vs. physician extender)
Number of subjects: 1401
Study: 26836840

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no vibration stimulus)
Number of subjects: 40
Study: 25005674

Group type: EXPERIMENTAL
Intervention: FII algorithm
Number of subjects: 11

Group type: COMPARATOR
Intervention: Carbohydrate counting
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 11
Study: 23178916

Group type: EXPERIMENTAL
Intervention: Adalimumab plus adjunctive topical therapy (calcipotriol/betamethasone dipropionate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab plus matching topical vehicle (monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 0
Study: 21128217

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention skills training (control condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theta/beta training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training of slow cortical potentials (SCP)
Number of subjects: 0
Study: 17487936

Group type: EXPERIMENTAL
Intervention: Rapid initiation of quetiapine (n = 139)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Conventional initiation of quetiapine (n = 130)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Rapid initiation of quetiapine
Number of subjects: 269

Group type: COMPARATOR
Intervention: Conventional initiation of quetiapine
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Both groups (Rapid and Conventional)
Number of subjects: 269
Study: 15578006

Group type: EXPERIMENTAL
Intervention: olanzapine (10‐20 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: amisulpride (400‐800 mg/day)
Number of subjects: 52
Study: 12388024

Group type: EXPERIMENTAL
Intervention: Fornix-based flap
Number of subjects: 30

Group type: COMPARATOR
Intervention: Limbus-based flap
Number of subjects: 30
Study: 10414731

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 7480923

Group type: EXPERIMENTAL
Intervention: Skin testing with T12E antigen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hemagglutination
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Skin testing with T12E antigen and Hemagglutination
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Skin testing, Immunofluorescence, and Hemagglutination
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: At least one of the exams (Skin testing, Hemagglutination, Immunofluorescence)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Skin testing and Immunofluorescence
Number of subjects: 120
Study: 10149538

Group type: EXPERIMENTAL
Intervention: Plasmapur separator with 0.5 mum pore size
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plasmapur separator with 0.6 mum pore size
Number of subjects: 100
Study: 6340453

Group type: EXPERIMENTAL
Intervention: Verapamil (0.2 mg/kg over 10 minutes)
Number of subjects: 25
Study: 31325962

Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy followed by insertion of Surgicel (Group CS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Laparoscopic drainage followed by insertion of Surgicel (Group DS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Laparoscopic drainage of the endometrioma (Group D)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Laparoscopic cystectomy of the endometrioma (Group C)
Number of subjects: 200
Study: 30144303

Group type: EXPERIMENTAL
Intervention: Antrostomy close to the sinus floor (group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antrostomy cranially positioned (group B)
Number of subjects: 24
Study: 27548249

Group type: COMPARATOR
Intervention: Iron therapy (6 mg·kg·day) plus placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Iron therapy (6 mg·kg·day) plus vitamin E (18 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Iron therapy (6 mg·kg·day) plus placebo and vitamin E
Number of subjects: 36
Study: 25246781

Group type: EXPERIMENTAL
Intervention: Telehealth program for 9 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 29
Study: 22353359

Group type: EXPERIMENTAL
Intervention: Vaginal fluid creatinine measurement in confirmed group (Group I)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Vaginal fluid creatinine measurement in suspected group (Group II)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Vaginal fluid creatinine measurement in control group (Group III)
Number of subjects: 180
Study: 20624806

Group type: EXPERIMENTAL
Intervention: Industry-funded RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral/educational trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Registered trials
Number of subjects: 0
Study: 17379118

Group type: EXPERIMENTAL
Intervention: Peripheral venous blood sampling
Number of subjects: 100

Group type: COMPARATOR
Intervention: Central venous blood sampling
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radial artery blood sampling
Number of subjects: 100
Study: 15876664

Group type: EXPERIMENTAL
Intervention: Compound probability density function parameters including the speckle factor and K distribution parameter
Number of subjects: 198
Study: 12081825

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage (35.1 kJ/kg)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 12% carbohydrate beverage (70.2 kJ/kg)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 10732589

Group type: EXPERIMENTAL
Intervention: Respirator
Number of subjects: 26

Group type: COMPARATOR
Intervention: Manual resuscitator
Number of subjects: 26
Study: 7828131

Group type: COMPARATOR
Intervention: VAD (vincristine, doxorubicin, and dexamethasone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VAD plus oral verapamil (VAD/v)
Number of subjects: 0
Study: 1964218

Group type: EXPERIMENTAL
Intervention: Local step-by-step intrapulmonary administration of glucocorticosteroids (GCS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study: 6153310

Group type: EXPERIMENTAL
Intervention: ajmalin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: propafenon
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Org 6001
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 30704885

Group type: COMPARATOR
Intervention: Single-bundle transpatellar tunnel technique (group A)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Double-anchor anatomic reconstruction technique (group B)
Number of subjects: 91
Study: 31406735

Group type: EXPERIMENTAL
Intervention: Medical documentaries (experimental group)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 277
Study: 27180210

Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (atDCS) over left pMTG/STG
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (atDCS) over left LIFG
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 24411286

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided compression (UGC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrasound-guided para-aneurysmal saline injection (PASI)
Number of subjects: 80
Study: 22101224

Group type: EXPERIMENTAL
Intervention: Exercising Together - a progressive, supervised strength training program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study: 19576776

Group type: EXPERIMENTAL
Intervention: Assisted plantarflexor push off
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Resisted plantarflexor push off
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control condition (no assistance or resistance)
Number of subjects: 11
Study: 18042570

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference exposure
Number of subjects: 0
Study: 15220031

Group type: EXPERIMENTAL
Intervention: donepezil (5 mg/day)
Number of subjects: 565

Group type: COMPARATOR
Intervention: donepezil (5 or 10 mg/day)
Number of subjects: 565
Study: 11468604

Group type: EXPERIMENTAL
Intervention: Intervention group (received a free 5-day course of prednisone, transportation vouchers, and a 48-hour telephone reminder)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 192
Study: 9683718

Group type: EXPERIMENTAL
Intervention: iodixanol (Visipaque; 320 mg I/ml)
Number of subjects: 398

Group type: COMPARATOR
Intervention: iohexol (Omnipaque; 300 mg I/ml)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Both iodixanol and iohexol
Number of subjects: 398
Study: 8023589

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs (NSAID)
Number of subjects: 102
Study: 3072358

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen 225 mg
Number of subjects: 0
Study: 31379311

Group type: EXPERIMENTAL
Intervention: Social Recovery Therapy (SRT)
Number of subjects: 75
Study: 29211509

Group type: EXPERIMENTAL
Intervention: Morning dosing of antihypertensive medications
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Evening dosing of antihypertensive medications
Number of subjects: 79